ProAir HFA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1.4M | 378 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 378 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (40 Years of Age or Older) With Chronic Obstructive Pulmonary Disease | Teva Pharmaceuticals USA, Inc. | $1.1M | 0 |
| A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma | Teva Pharmaceuticals USA, Inc. | $305,160 | 3 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.4M
- Total Doctors 3
- Transactions 378
About ProAir HFA
ProAir HFA is a drug associated with $1.4M in payments to 3 healthcare providers, recorded across 378 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2018 to 2018. In 2018, $1.4M was paid across 378 transactions to 3 doctors.
The most common payment nature for ProAir HFA is "Unspecified" ($1.4M, 100.0% of total).
ProAir HFA is associated with 2 research studies, including "A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (40 Years of Age or Older) With Chronic Obstructive Pulmonary Disease" ($1.1M).